Logo image of SVII

SPRING VALLEY ACQUISITION-A (SVII) Stock Fundamental Analysis

NASDAQ:SVII - Nasdaq - KYG837521080 - Common Stock - Currency: USD

11.79  +0.12 (+1.03%)

Fundamental Rating

2

Overall SVII gets a fundamental rating of 2 out of 10. We evaluated SVII against 0 industry peers in the Unkown industry. While SVII seems to be doing ok healthwise, there are quite some concerns on its profitability. SVII is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

SVII had positive earnings in the past year.
In the past year SVII has reported a negative cash flow from operations.
SVII Yearly Net Income VS EBIT VS OCF VS FCFSVII Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 2M 4M 6M 8M 10M

1.2 Ratios

Industry RankSector Rank
ROA 26.09%
ROE 27.92%
ROIC N/A
ROA(3y)10.36%
ROA(5y)N/A
ROE(3y)11.02%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SVII Yearly ROA, ROE, ROICSVII Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 10 20

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SVII so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SVII Yearly Profit, Operating, Gross MarginsSVII Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

SVII has less shares outstanding than it did 1 year ago.
There is no outstanding debt for SVII. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SVII Yearly Shares OutstandingSVII Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 10M 20M 30M
SVII Yearly Total Debt VS Total AssetsSVII Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

SVII has an Altman-Z score of 40.26. This indicates that SVII is financially healthy and has little risk of bankruptcy at the moment.
SVII has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 40.26
ROIC/WACCN/A
WACCN/A
SVII Yearly LT Debt VS Equity VS FCFSVII Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 50M 100M 150M 200M

2.3 Liquidity

A Current Ratio of 0.33 indicates that SVII may have some problems paying its short term obligations.
SVII has a Quick Ratio of 0.33. This is a bad value and indicates that SVII is not financially healthy enough and could expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 0.33
Quick Ratio 0.33
SVII Yearly Current Assets VS Current LiabilitesSVII Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 500K 1M 1.5M 2M

More info and screens

1

3. Growth

3.1 Past

SVII shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 33.16%, which is quite impressive.
EPS 1Y (TTM)33.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-41.04%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 24.06 indicates a rather expensive valuation of SVII.
Compared to an average S&P500 Price/Earnings ratio of 25.82, SVII is valued at the same level.
Industry RankSector Rank
PE 24.06
Fwd PE N/A
SVII Price Earnings VS Forward Price EarningsSVII Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SVII Per share dataSVII EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SVII!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SPRING VALLEY ACQUISITION-A

NASDAQ:SVII (5/23/2025, 8:57:45 PM)

11.79

+0.12 (+1.03%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)05-12 2025-05-12
Earnings (Next)N/A N/A
Inst Owners38.38%
Inst Owner Change-34.33%
Ins Owners1.21%
Ins Owner Change0%
Market Cap116.49M
AnalystsN/A
Price TargetN/A
Short Float %0.22%
Short Ratio0.32
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 24.06
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.77
P/tB 4.77
EV/EBITDA N/A
EPS(TTM)0.49
EY4.16%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.08
FCFYN/A
OCF(TTM)-0.08
OCFYN/A
SpS0
BVpS2.47
TBVpS2.47
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 26.09%
ROE 27.92%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)10.36%
ROA(5y)N/A
ROE(3y)11.02%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.33
Quick Ratio 0.33
Altman-Z 40.26
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)33.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-41.04%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y2.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-51.76%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-51.76%
OCF growth 3YN/A
OCF growth 5YN/A